Indivior Pharmaceuticals Inc
INDVNASDAQHealthcare● Active
$38.22
+$0.61(+1.61%)
Market Cap$4.8B
P/E Ratio—
52W High$41
52W Low$13.42
Indivior Pharmaceuticals Inc (INDV) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · INDV · as of 2026-06-08
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $1.24B | $1.19B | $1.09B | $0.90B | $0.79B |
| Cost of Revenue | $0.25B | $0.23B | $0.17B | $0.15B | $0.13B |
| Gross Profit | $0.99B | $0.96B | $0.92B | $0.75B | $0.66B |
| Gross Margin %(computed) | 80.15% | 80.56% | 84.08% | 83.24% | 83.94% |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.11B | $0.12B | $0.07B | $0.05B |
| G&A Expenses | $0.32B | $0.36B | $0.33B | $0.25B | $0.24B |
| Total Operating Expenses | $0.73B | $0.93B | $1.07B | $0.83B | $0.45B |
| Operating Income | $0.27B | $0.03B | ($0.16B) | ($0.08B) | $0.21B |
| Operating Margin %(computed) | 21.39% | 2.69% | -14.27% | -8.99% | 26.93% |
| Interest Income | $0.02B | $0.02B | $0.04B | $0.02B | $0.00B |
| Interest Expense | $0.04B | $0.04B | $0.04B | $0.03B | $0.03B |
| Income Before Tax | $0.24B | $0.01B | ($0.15B) | ($0.09B) | $0.19B |
| Income Tax Expense | $0.03B | $0.01B | ($0.02B) | ($0.04B) | ($0.01B) |
| Net Income | $0.21B | $0.00B | ($0.13B) | ($0.04B) | $0.20B |
| Net Margin %(computed) | 16.95% | 0.17% | -11.80% | -4.88% | 25.92% |
| Per Share & EBITDA | |||||
| EPS (Basic) | $1.68 | $0.02 | $0.01 | $-0.37 | $1.38 |
| Wtd Avg Shares | 0.13B | 0.13B | 0.14B | 0.14B | 0.15B |
| EBITDA | $0.30B | $0.08B | ($0.10B) | ($0.05B) | $0.24B |
| EBITDA Margin %(computed) | 24.54% | 7.07% | -9.06% | -5.11% | 30.09% |
Data source: Financial Modeling Prep · Last updated: 2026-06-08 · USD · B
Explore more Indivior Pharmaceuticals Inc data
About Indivior Pharmaceuticals Inc (INDV) Income Statement
Indivior Pharmaceuticals Inc (INDV) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, INDV reported revenue of $1.24B, gross profit of $0.99B (gross margin 80.15%), and net income of $0.21B — a net profit margin of 16.95%.
Frequently asked questions
INDV · 4 questionsIndivior Pharmaceuticals Inc (INDV) reported revenue of $1.24B for 2025, up 4.3% year-over-year.
INDV revenueINDV salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-08